Search 

Ethypharm is a rapidly growing specialty pharma company with nascent commercial operations, an expanding portfolio of marketed products, a unique drug development expertise and a broad and advanced pipeline.

Ethypharm now incorporating Martindale Pharma of the UK focuses on pain management and treatment for addiction, particularly opioids and alcohol use disorder; with the current short-term goal to commercialize its own or in-licensed drugs in a number of European countries.

In other therapeutic areas, mainly oncology, Ethypharm has a strong capability in developing and manufacturing specific and "complex" drug formulations in order to market them through global or local partners.

Ethypharm’s headquarters are located in Paris, France and has a very strong affiliate in the UK, it owns two manufacturing plants in France, one in China, and an affiliate in the USA.
 
Ethypharm is actively seeking:

• Licensing-in/acquisition opportunities in pain and addiction (to opioids, alcohol, tobacco) , critical care, complex generics, brands, late stage NCEs, Steriles/Injectables, Hospital products);

Leader in consensus forecast analysis of the biotech and pharma sector providing trusted insight into global performance to 2024.

George Health Enterprises is the commercial arm of The George Institute for Global Health. George Health Medicines (a wholly owned subsidiary of GHE)  is focussed on the late stage development and key territory registration of pharmaceutical products which have resulted from The George Institute's ground-breaking research into the treatment of non-communicable diseases. George Health Medicines is seeking appropriate commercial partners globally for the medicines which it developes. The short term pipeline includes innovative medicines for the prophylaxis of cardiovascular disease and for the primary treatment of hypertension and Type II diabetes.

Imperial Innovations is the Technology Transfer office for Imperial College London and selected NHS Trusts around London. Imperial College London is ranked in the world's top ten (QS Rankings 2018) and is the second-most innovative university in Europe (Reuters 2018).

We work closely with academic inventors to bring their research projects to market. We work with a diverse range of technologies, from diagnostics to surgical tools, therapeutics to digital healthcare solutions. We are experts in identifying, evaluating and backing technologies that meet industrial market need.

-We assess inventions, considering commercial potential, the state of the market and development requirements

-We protect intellectual property through patents and other appropriate forms of intellectual property protection

-We provide advice on establishing proof of concept, using our commercial experience to inform inventors about what businesses want to see

-We may provide development funding or support inventors in their applications for funding from other sources

-We advise on IP and commercial strategy

-We manage the licensing process (including negotiations and post-deal administration)

-Our Venture Support Unit establishes new businesses, finds mentors and management and provides access to preferred suppliers

-Above all we are flexible in our support – capable of executing novel deals and providing unique support where required.

Company Description

Napp is part of a privately owned global network of independent associated companies. In Europe, Mundipharma and Napp have sales revenues of over $1bn combined.

We are an asset led, highly entrepreneurial and commercially minded business that is focussed on providing innovative medicines to UK patients across all parts of the NHS. We are ambitious to be a leading partnership selling organisation; creating strong and effective partnerships with commercial partners, healthcare providers and patients.

Structured in Business Units around our four commercial platforms of Primary Care, Specialty Care, Biosimilars and Branded Generics, we are able to make fast decisions and focus on the right products in the right areas.

Qdem, our branded generics house is a wholly owned subsidiary of Napp. Qdem has a team of 8 dedicated KAMs who cover the whole of the UK. We have had great success in gaining and maintaining market share with our branded generics Butec®, Longtec® and Shortec®.

Our other leading brands at Napp include Invokana® for Type II diabetes, Flutiform® for asthma and Remsima®, Truxima® and Herzuma® (biosimilars of infliximab, rituximab and trastuzumab).

We offer

Napp has exceptionally capable marketing, sales and market access matrix teams, which effectively build and grow originator products in competitive indication areas, and enjoy an excellent reputation in the NHS and with GPs and UK KOLs. Mundipharma has both a heritage and reputation for excellence in pharmaceutical marketing and sales around the world, and an excellent reputation with healthcare practitioners throughout our region.

We have the support and remit to grow quickly our Qdem UK generics business through the in-licensing and acquisition of assets. Our Qdem marketing and sales team consists of originator salespeople from within and outside of the Napp Pharmaceuticals business with superb payer, formulary and healthcare practitioner contacts, and has excellent experience for the launch of both complex and value added branded generics in the UK.

We are interested in:

We are looking for dossiers and supply across all therapy areas (but particularly respiratory, urology, CNS & gastroenterology) for the following:

Value add generics, with novel dose forms or strengths

Generic drug delivery devices

Other complex delivery forms

Delayed or complex release forms across all therapy areas

Napp is keen to explore partnership opportunities for NCEs, biologics, biosimilars, orphan medicines and generics.

We are not interested in

Immediate release generics.

Hospital tender only generics.

API. CRO, CSO or CMO services.